CompletedPHASE1, PHASE2NCT01752049

Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept

Studying Hereditary hemorrhagic telangiectasia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Unity Health Toronto
Principal Investigator
Marie E Faughnan, MD MSc FRCPC
Unity Health Toronto
Intervention
Topical timolol maleate(drug)
Enrollment
5 target
Eligibility
18 years · All sexes
Timeline
20132019

Study locations (1)

Collaborators

University of California, San Francisco · The Hospital for Sick Children · University of Toronto · Sunnybrook Health Sciences Centre · Toronto Metropolitan University · National Institute of Neurological Disorders and Stroke (NINDS)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01752049 on ClinicalTrials.gov

Other trials for Hereditary hemorrhagic telangiectasia

Additional recruiting or active studies for the same condition.

See all trials for Hereditary hemorrhagic telangiectasia

← Back to all trials